Literature DB >> 22295172

Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011).

Xiu-Yi Zhi1, Yi-Long Wu, Hong Bu, Gang Cheng, Ying Cheng, Xiang Du, Bao-Hui Han, Ge-Ning Jiang, Shun-Chang Jiao, De-Ruo Liu, Lun-Xu Liu, You Lu, Sheng-Lin Ma, Yuan-Kai Shi, Chang-Li Wang, Jie Wang, Tian-You Wang, Yue Yang, Qing-Hua Zhou.   

Abstract

Entities:  

Year:  2012        PMID： 22295172      PMCID： PMC3256545          DOI： 10.3978/j.issn.2072-1439.2010.08.01

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Being an oncologist in China: my notes about cancer treatment in China.

Authors:  Aiwen Wu
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

2.  Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.

Authors:  Weishuai Liu; Yuejuan Shao; Bingqing Guan; Jianlei Hao; Xianjiang Cheng; Kai Ji; Kun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Lung cancer treatment disparities in China: a question in need of an answer.

Authors:  Lu-Lu Yang; Xu-Chao Zhang; Xue-Ning Yang; Jin-Ji Yang; Zhen Wang; Hua-Jun Chen; Hong-Hong Yan; Chong-Rui Xu; Ji-Lin Guan; Yan-Yan He; Wen-Zhao Zhong; She-Juan An; Yi-Long Wu
Journal:  Oncologist       Date:  2014-09-15

Review 4.  Medical management of lung cancer: Experience in China.

Authors:  Yuankai Shi; Yan Sun
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

5.  Age-related changes in CD4+CD25+FOXP3+ regulatory T cells and their relationship with lung cancer.

Authors:  Pan-Fei Hou; Li-Jing Zhu; Xiao-Ying Chen; Zhu-Qiang Qiu
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 6.  Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.

Authors:  BaoHui Han; LuLu Yang; Xin Wang; LuanDi Yao
Journal:  Onco Targets Ther       Date:  2018-04-12       Impact factor: 4.147

Review 7.  Respiratory medicine in China: progress, challenges, and opportunities.

Authors:  Chen Wang; Fei Xiao; Renli Qiao; Ying H Shen
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

8.  Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Shun Lu; Yan Yu; Gisoo Barnes; Xiusong Qiu; Yuanyuan Bao; Boxiong Tang
Journal:  Cancer J       Date:  2022 Mar-Apr 01       Impact factor: 3.360
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.